
Anpario plc, founded in 1996 and based in Worksop, United Kingdom, specializes in the global production and distribution of natural feed additives designed to enhance animal health, hygiene, and nutrition. Previously operating as Kiotech International plc until its rebranding in November 2011, the company offers a diverse product portfolio across several categories. Its 'Health and Performance' line features products that bolster animal gut health, including phytogenic and acid-based eubiotics, and omega fatty acids, available under brands such as Orego-Stim, Optomega, pHorce, Salgard, Salkil, Genex, and Optimax. The 'Feed Quality' segment provides solutions like enzymes, antioxidants, pellet binders, mould inhibitors, and acid-based eubiotics, marketed as pHorce, Salkil, Salgard, Oxigard, Moldgard, and Mastercube. For 'Hygiene and Insect Control', Anpario supplies water sanitation tablets, all-natural insect control powders, and natural drying agents, sold under names like Credence, Mitex, Red Lite, and Clean & Dry, which contribute to minimizing environmental microbial burdens and supporting animal gut health and overall performance. Furthermore, the 'Toxin Management' category offers mycotoxin binders, including products under the Anpro, Ultrabond, and Neutox brands. Anpario plc maintains a broad international footprint, conducting operations across the Americas, Asia, Europe, the Middle East, and Africa.
Anpario plc trades as ANP.L on LSE. The company is classified in Consumer Defensive / Packaged Foods and reports in GBP.
The current profile places the business in Packaged Foods. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.
Latest available fiscal data shows £47.17M of revenue and £6.75M of net income.
Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.
The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.
Anpario plc can be compared against peers such as Cake Box Holdings Plc, Chapel Down Group Plc, Fevara plc, R.E.A. Holdings plc, R.E.A. Holdings plc, MicroSalt Plc.
A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.
Current signals to investigate include market capitalization of £87.77M, beta of 1.05, and return on equity of +16.5%.
This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.
Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.
ANP.L currently shows total debt of £244,000 and beta of 1.05. Missing data should be treated as a research gap, not as low risk.
Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.
No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.
Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.
No recent SEC-style filings are available for this symbol yet.
Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.
Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.
Company website: https://www.anpario.com
For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.